PMID- 36627777
OWN - NLM
STAT- MEDLINE
DCOM- 20230619
LR  - 20230619
IS  - 2212-3873 (Electronic)
IS  - 1871-5303 (Linking)
VI  - 23
IP  - 8
DP  - 2023
TI  - Use of Saliva to Assess the Adherence to Treatment with Oral Hypoglycemic Agents 
      in Patients with Type 2 Diabetes.
PG  - 1068-1076
LID - 10.2174/1871530323666230110123143 [doi]
AB  - BACKGROUND: The diagnosis of Type 2 Diabetes Mellitus (T2DM) is made by 
      demonstrating the hypoglycemic condition, which involves the determination of 
      plasma glucose, and the follow-up of hypoglycemic treatment is performed by 
      assessing the glycated hemoglobin (HbA1c) concentration. AIM: The aim of this 
      study was to evaluate the saliva as an alternative sample in assessing the 
      adherence to treatment with oral hypoglycemic agents in patients with Type 2 
      Diabetes. METHODS: We selected 68 patients with T2DM, who were subjected to 
      venous blood and saliva collection, in addition to answering a standardized 
      questionnaire on adherence to hypoglycemic treatment. Laboratory tests performed 
      on saliva, whole blood, serum or plasma included assessment of glycemia, urea, 
      creatinine, uric acid, total cholesterol, HDL-cholesterol, LDL-cholesterol, 
      VLDL-cholesterol, and glycated hemoglobin. RESULTS: It was concluded that 82% of 
      the patients adhered to hypoglycemic treatment based on glycated hemoglobin 
      concentration (cut-off value of 7.0%). Comparing the groups that adhered to 
      hypoglycemic treatment and those that did not adhere, statistical differences 
      (P<0.05) were observed in the glucose, HDL-cholesterol, triglycerides, and 
      insulin use (insulin therapy) parameters. Plasma glucose and urea serum 
      concentration showed positive correlations when compared to saliva samples. 
      Regarding the questionnaire, it was found that 35% of the patients presented 
      positive screening for belief barriers and 83% positive score for recall 
      barriers, and the positive screening correlated with glycated hemoglobin. 
      CONCLUSION: Data have shown that it is possible to use saliva as an alternative 
      sample to the laboratory assessment of hypoglycemic treatment adherence in T2DM 
      patients.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - de Faria Baltazar, Heloisa
AU  - de Faria Baltazar H
AD  - Department of Pharmaceutical Science, Universidade Federal de Sao Paulo/UNIFESP, 
      Diadema, Brazil.
FAU - Fonseca, Fernando Luiz Affonso
AU  - Fonseca FLA
AD  - Department of Pharmaceutical Science, Universidade Federal de Sao Paulo/UNIFESP, 
      Diadema, Brazil.
AD  - Clinical Analysis Laboratory, Centro Universitario Saude ABC, Santo Andre, 
      Brazil.
FAU - Castelo, Paula Midori
AU  - Castelo PM
AD  - Department of Pharmaceutical Science, Universidade Federal de Sao Paulo/UNIFESP, 
      Diadema, Brazil.
FAU - da Costa Aguiar Alves, Beatriz
AU  - da Costa Aguiar Alves B
AD  - Department of Pharmaceutical Science, Universidade Federal de Sao Paulo/UNIFESP, 
      Diadema, Brazil.
FAU - Gascon, Thais
AU  - Gascon T
AD  - Clinical Analysis Laboratory, Centro Universitario Saude ABC, Santo Andre, 
      Brazil.
FAU - da Veiga, Glaucia Luciano
AU  - da Veiga GL
AD  - Clinical Analysis Laboratory, Centro Universitario Saude ABC, Santo Andre, 
      Brazil.
FAU - Pereira, Edimar Cristiano
AU  - Pereira EC
AD  - Department of Pharmaceutical Science, Universidade Federal de Sao Paulo/UNIFESP, 
      Diadema, Brazil.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Endocr Metab Immune Disord Drug Targets
JT  - Endocrine, metabolic & immune disorders drug targets
JID - 101269157
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Cholesterol, LDL)
RN  - 8W8T17847W (Urea)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Glycated Hemoglobin
MH  - Blood Glucose
MH  - Saliva
MH  - Hypoglycemic Agents
MH  - Insulin
MH  - Cholesterol, LDL
MH  - Urea
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - VLDL
OT  - glycated hemoglobin
OT  - hypoglycemia
OT  - pharmacotherapeutic
OT  - saliva
EDAT- 2023/01/12 06:00
MHDA- 2023/06/19 13:08
CRDT- 2023/01/11 00:32
PHST- 2022/06/13 00:00 [received]
PHST- 2022/11/03 00:00 [revised]
PHST- 2022/11/08 00:00 [accepted]
PHST- 2023/06/19 13:08 [medline]
PHST- 2023/01/12 06:00 [pubmed]
PHST- 2023/01/11 00:32 [entrez]
AID - EMIDDT-EPUB-128710 [pii]
AID - 10.2174/1871530323666230110123143 [doi]
PST - ppublish
SO  - Endocr Metab Immune Disord Drug Targets. 2023;23(8):1068-1076. doi: 
      10.2174/1871530323666230110123143.